62965-57-5Relevant articles and documents
The Strecker reaction coupled to Viedma ripening: A simple route to highly hindered enantiomerically pure amino acids
Baglai, Iaroslav,Leeman, Michel,Wurst, Klaus,Kaptein, Bernard,Kellogg, Richard M.,Noorduin, Willem L.
supporting information, p. 10832 - 10834 (2018/10/02)
The Strecker reaction is broadly used for the preparation of α-amino acids. However, control of enantioselectivity remains challenging. We here couple the Strecker reaction to Viedma ripening for the absolute asymmetric synthesis of highly sterically hindered α-amino acids. As proof-of-principle, the enantiomerically pure α-amino acids tert-leucine and α-(1-adamantyl)glycine were obtained.
Dynamic kinetic resolution of α-aminonitriles to form chiral α-amino acids
Yasukawa, Kazuyuki,Hasemi, Ryuji,Asano, Yasuhisa
supporting information; scheme or table, p. 2328 - 2332 (2011/10/19)
We have succeeded in the enzymatic synthesis of (R)-α-aminobutyric acid from racemic α-aminobutyronitrile. This has been demonstrated by the use of non-stereoselective nitrile hydratase (NHase) from Rhodococcus opacus 71D, D-aminopeptidase from Ochrobactrum anthropi C1-38 and α-amino-ε- caprolactam (ACL) racemase from Achromobacter obae. Racemic α- aminobutyronitrile was completely converted in 6 h at 30 °C to (R)-α-aminobutyric acid whose optical purity was more than 99%. (S)-α-Aminobutyric acid was also synthesized from α- aminobutyronitrile by NHase, ACL racemase and L-amino acid amidase from Brevundimonas diminuta TPU 5720. In a similar manner, other (R)- or (S)-α-amino acids with more than 97.5% ee could be synthesized from the corresponding α-aminonitriles. This is the first report on the dynamic kinetic resolution (DKR) of α-aminonitriles to form chiral α-amino acids. The key enzyme in this DKR is non-stereoselective NHase, which had been newly screened from soil samples, and its gene cloned. Copyright
BENZIMIDAZOLONE DERIVATIVES
-
Page/Page column 29, (2009/12/23)
This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective am